Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD)

Xin Xin; Cheng Chen; Yi-Yang Hu; Qin Feng

doi:10.1016/j.biopha.2019.109047

Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD)

Biomed Pharmacother. 2019 Sep:117:109047. doi: 10.1016/j.biopha.2019.109047. Epub 2019 Jun 5.

Authors

Xin Xin¹, Cheng Chen¹, Yi-Yang Hu², Qin Feng³

Affiliations

¹ Institute of Liver diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
² Institute of Liver diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, 201203, China; Key Laboratory of Liver and Kidney Diseases, Shanghai University of Traditional Chinese Medicine, Ministry of Education, Shanghai, 201203, China.
³ Institute of Liver diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, 201203, China; Key Laboratory of Liver and Kidney Diseases, Shanghai University of Traditional Chinese Medicine, Ministry of Education, Shanghai, 201203, China. Electronic address: fengqin1227@163.com.

PMID: 31176163
DOI: 10.1016/j.biopha.2019.109047

Abstract

NAFLD is a vital health problem worldwide; however, no effective treatment is currently available for NAFLD. Intensive studies have indicated the efficacy of genistein (GE), a bioactive isoflavone extracted from soy, in treating NAFLD. In addition to its oestrogen-like effects, GE is known to have multiple molecular effects, for instance, lipid and glucose metabolism-promoting effects and activities against lipid peroxidation, inflammation, fibrosis, and NAFLD-related tumours. Here, this review summarizes the potential role of GE in the treatment and prevention of NAFLD and some of the currently known targets and signalling pathways of GE in NAFLD.

Keywords: Genistein; Non-alcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Review; Soy.

Publication types

Review

MeSH terms

Animals
Carcinogenesis / drug effects
Carcinogenesis / pathology
Clinical Trials as Topic
Genistein / chemistry
Genistein / pharmacology
Genistein / therapeutic use*
Humans
Non-alcoholic Fatty Liver Disease / drug therapy*
Protective Agents / chemistry
Protective Agents / pharmacology
Protective Agents / therapeutic use*

Substances

Protective Agents
Genistein